{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:22:43Z","timestamp":1792142563584,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.coph.2011.07.001","type":"journal-article","created":{"date-parts":[[2011,8,2]],"date-time":"2011-08-02T04:27:53Z","timestamp":1312259273000},"page":"457-463","source":"Crossref","is-referenced-by-count":74,"title":["A new evolutionary and pharmacokinetic\u2013pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs"],"prefix":"10.1016","volume":"11","author":[{"given":"Jotam G","family":"Pasipanodya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2011.07.001_bib0005","series-title":"Global Tuberculosis Control: WHO Report 2010","author":"World Health Organization, Geneva, Switzerland","year":"2010"},{"key":"10.1016\/j.coph.2011.07.001_bib0010","first-page":"10","article-title":"How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis","volume":"2","author":"Mitchison","year":"1998","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.coph.2011.07.001_bib0015","first-page":"939","article-title":"The early bactericidal activity of drugs in patients with pulmonary tuberculosis","volume":"121","author":"Jindani","year":"1980","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.coph.2011.07.001_bib0020","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/infdis\/171.4.954","article-title":"Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis","volume":"171","author":"Morris","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coph.2011.07.001_bib0025","series-title":"Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard","author":"Clinical and Laboratory Standards Institute","year":"2003"},{"key":"10.1016\/j.coph.2011.07.001_bib0030","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00228-006-0141-z","article-title":"Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients","volume":"62","author":"Wilkins","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.coph.2011.07.001_bib0035","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1086\/424849","article-title":"Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling","volume":"190","author":"Gumbo","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coph.2011.07.001_bib0040","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1128\/AAC.49.8.3178-3181.2005","article-title":"Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance","volume":"49","author":"Gumbo","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.001_bib0045","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1086\/510247","article-title":"Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth","volume":"195","author":"Gumbo","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coph.2011.07.001_bib0050","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/AAC.01533-06","article-title":"Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.001_bib0055_1","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1128\/AAC.01681-08","article-title":"Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs","volume":"53","author":"Gumbo","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.001_bib0060_1","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1128\/AAC.01567-09","article-title":"Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used","volume":"54","author":"Pasipanodya","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.001_bib0065","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1128\/AAC.00185-07","article-title":"Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.001_bib0070_1","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1086\/651377","article-title":"Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol","volume":"201","author":"Srivastava","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coph.2011.07.001_bib0075","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1128\/AAC.48.8.2951-2957.2004","article-title":"Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis","volume":"48","author":"Jayaram","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.001_bib0080","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118-2124.2003","article-title":"Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis","volume":"47","author":"Jayaram","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.001_bib0085_1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00749-10","article-title":"An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future","volume":"55","author":"Pasipanodya","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.001_bib0090_1","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1128\/AAC.01520-08","article-title":"Pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs: a population modeling and Monte Carlo simulation study","volume":"53","author":"Goutelle","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.001_bib0095","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1128\/AAC.41.12.2670","article-title":"Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide","volume":"41","author":"Peloquin","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.001_bib0100_1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2125.2011.03940.x","article-title":"Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients","volume":"72","author":"Wilkins","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.coph.2011.07.001_bib0105","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1128\/AAC.00461-07","article-title":"Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption","volume":"52","author":"Wilkins","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.001_bib0110","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1128\/AAC.49.5.1733-1738.2005","article-title":"Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?","volume":"49","author":"Kinzig-Schippers","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.001_bib0115","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1128\/AAC.01123-07","article-title":"In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis","volume":"51","author":"Almeida","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.001_bib0120","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1128\/JB.188.8.3159-3161.2006","article-title":"Identification of Nudix hydrolase family members with an antimutator role in Mycobacterium tuberculosis and Mycobacterium smegmatis","volume":"188","author":"Dos","year":"2006","journal-title":"J Bacteriol"},{"key":"10.1016\/j.coph.2011.07.001_bib0125","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1128\/IAI.71.2.997-1000.2003","article-title":"DNA alkylation damage as a sensor of nitrosative stress in Mycobacterium tuberculosis","volume":"71","author":"Durbach","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.coph.2011.07.001_bib0130","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0966-842X(97)01157-8","article-title":"To be a mutator, or how pathogenic and commensal bacteria can evolve rapidly","volume":"5","author":"Taddei","year":"1997","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.coph.2011.07.001_bib0135","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3201\/eid0907.020803","article-title":"Mutations in putative mutator genes of Mycobacterium tuberculosis strains of the W-Beijing family","volume":"9","author":"Rad","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coph.2011.07.001_bib0140_1","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/ng.811","article-title":"Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection","volume":"43","author":"Ford","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.coph.2011.07.001_bib0145","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1086\/518046","article-title":"Isoniazid activity is terminated by bacterial persistence","volume":"195","author":"Mitchison","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coph.2011.07.001_bib0150","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1086\/605605","article-title":"Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig","volume":"200","author":"Ahmad","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coph.2011.07.001_bib0155_1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1086\/595689","article-title":"Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis","volume":"48","author":"Cattamanchi","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2011.07.001_bib0160_1","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201011-1924OC","article-title":"Rifampicin reduces susceptibility to ofloxacin in rifampicin resistant Mycobacterium tuberculosis through efflux","author":"Louw","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2011.07.001_bib0165","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(02)09742-8","article-title":"Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial","volume":"360","author":"Benator","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2011.07.001_bib0170","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1164\/rccm.200503-417OC","article-title":"Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis","volume":"173","author":"Burman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2011.07.001_bib0175","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1128\/AAC.00133-10","article-title":"Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model","volume":"54","author":"Drusano","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2011.07.001_bib0180","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1128\/AAC.01687-10","article-title":"Saturability of granulocyte kill of Pseudomonas aeruginosa in a murine model of pneumonia","volume":"55","author":"Drusano","year":"2011","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147148921100097X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147148921100097X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T13:22:59Z","timestamp":1560432179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147148921100097X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S147148921100097X"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2011.07.001","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}